Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Department of Paediatrics, Mater Dei Hospital, Msida, Malta.
Drugs. 2017 Nov;77(17):1881-1896. doi: 10.1007/s40265-017-0828-8.
MenACWY-TT (Nimenrix) is a quadrivalent meningococcal tetanus toxoid conjugate vaccine licensed in Europe for active immunisation of individuals aged ≥ 6 weeks against invasive disease caused by Neisseria meningitidis capsular groups A, C, W and Y. MenACWY-TT is the first quadrivalent conjugate vaccine to be approved in Europe for use in infants as young as 6 weeks of age. Numerous phase II-IIIb clinical studies showed that intramuscular MenACWY-TT administered as primary or booster vaccination was highly immunogenic for all four vaccine capsular groups and had an acceptable reactogenicity profile in individuals aged 6 weeks to ≥ 56 years. MenACWY-TT is as immunogenic and safe as other previously licensed monovalent capsular group C or quadrivalent capsular groups A, C, W and Y meningococcal vaccines and can be coadministered with other routine vaccines without adversely affecting the immunogenicity or safety profiles of either vaccine. Current data indicate that primary and booster vaccination with MenACWY-TT is a valuable and safe option for broadening meningococcal protection against four capsular groups across a broad age range, starting as early as 6 weeks of age.
MenACWY-TT（Nimenrix）是一种四价脑膜炎奈瑟菌破伤风类毒素结合疫苗，在欧洲获准用于 6 周龄及以上个体主动免疫，预防由脑膜炎奈瑟菌 A、C、W 和 Y 血清群引起的侵袭性疾病。MenACWY-TT 是首个在欧洲获准用于 6 周龄婴儿的四价结合疫苗。大量 II-IIIb 期临床研究表明，6 周龄至 56 岁以上个体肌内接种 MenACWY-TT 作为基础免疫或加强免疫，对所有 4 个疫苗血清群均具有高度免疫原性，且具有可接受的不良反应谱。MenACWY-TT 的免疫原性和安全性与其他先前获得许可的单价 C 群或四价 A、C、W 和 Y 群脑膜炎球菌疫苗相当，且可与其他常规疫苗同时接种，不会对任一疫苗的免疫原性或安全性产生不利影响。现有数据表明，6 周龄起，对广泛年龄范围的个体进行 MenACWY-TT 的基础免疫和加强免疫，是一种有价值且安全的选择，可扩大针对 4 个血清群的脑膜炎球菌保护。
